
Ceptur: Innovating unique genetic medicines for unaddressed diseases.
Ceptur Therapeutics, founded with a mission to innovate unique genetic medicines, focuses on developing treatments for patients with unaddressed diseases. The company aims to harness advanced genetic technologies to create differentiated therapies that address unmet medical needs. Their market focus includes rare genetic disorders and other conditions that currently lack effective treatment options.
Notable affiliated individuals and investors in Ceptur Therapeutics include prominent figures in the biotech industry, though specific names are not disclosed. The company has achieved significant milestones in its research and development efforts, contributing to the broader field of genetic medicine. Ceptur's impact lies in its potential to transform the lives of patients with rare and underserved conditions through cutting-edge genetic therapies.

CuraSen Therapeutics
curasen.com

Triplet Therapeutics
triplettx.com

Jaguar Gene Therapy

PTC Therapeutics
ptcbio.com

Cogent Biosciences
cogentbio.com

Courage Therapeutics

Aro Biotherapeutics
arobiotx.com

Encoded Therapeutics

Star Therapeutics

ReviR Therapeutics
revirtx.com
Tisento Therapeutics

Stealth BioTherapeutics
stealthbt.com

Guardian Therapeutics

Spheringenics

Citrine Medicine
Companies similar to Ceptur Therapeutics include CuraSen Therapeutics, Triplet Therapeutics, Jaguar Gene Therapy and PTC Therapeutics.
Ceptur Therapeutics was founded in 2008.
Ceptur Therapeutics' headquarters is located in Hillsborough Township, NJ, US.
Ceptur Therapeutics' most recent funding round was for $75M (USD) in January 2022.
As of Jan 19, 2022, Ceptur Therapeutics has raised a total of $81.2M (USD).
Ceptur Therapeutics has 31 employees as of Feb 5, 2024.